Abivax To Launch ‘Triple-Action’ COVID-19 Therapy Trial

Data Show Anti-inflammatory ABX464 inhibits SARS-CoV-2 Viral Replication In Lung

 
• By Sten Stovall

Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.    

Covid19_Lungs_Vial
Abivax says ABX464 has ‘unique’ triple action to treat COVID-19 patients • Source: Shutterstock

More from COVID-19

More from Scrip